| Age, yrs |
63 (52–72)*
|
| Male |
10 (91%) |
| Body mass index, kg/m2
|
25.7 ± 3.4 |
| Hypertension |
7 (64%) |
| Diabetes mellitus |
6 (55%) |
| Hyperlipidemia |
3 (27%) |
| Prior myocardial infarction |
0 |
| Prior percutaneous coronary intervention |
1 (9%) |
| Prior coronary artery bypass grafting |
0 |
| Medical treatment |
|
| Aspirin |
11 (100%) |
| Clopidogrel |
5 (45%) |
| Ticagrelor |
6 (55%) |
| Statins |
11 (100%) |
| Nitrate |
5 (45%) |
| Beta-blockers |
4 (36%) |
| NYHA functional class |
|
| Class I |
7 (64%) |
| Class II |
4 (36%) |
| Class III |
0 |
| Class IV |
0 |
| Left ventricular ejection fraction, % |
65 (65–68)*
|
| Heart rate, beat/min |
73.9 ± 7.9 |
| Systolic blood pressure, mmHg |
137.2 ± 19.3 |
| C-reative protein, mg/dL |
1.75 (0.93–2.97)*
|
| Leukocyte, × 109/L |
6.23 (5.76–7.38)*
|
| Red blood cells, × 1012/L |
4.74 (4.47–5.01)*
|
| Hemoglobin, g/L |
150 (139–152)*
|
| Platelets, × 109/L |
234 (164–250)*
|
| Neutrophil percentage, % |
68.9 (66.9–75.5)*
|
| B-type natriuretic peptide, ng/L |
37 (9–140)*
|
| Albumin, U/L |
42 (41.2–46)*
|
| Aspartate aminotransferase, U/L |
18 (16–21)*
|
| Alanine aminotransferase, U/L |
21 (15–24)*
|
| Total bilirubin, μmol/L |
11.66 (8.24–12.39)*
|
| Urea, μmol/L |
6.03 (5.78–7.48)*
|
| Creatinine, μmol/L |
79 (74.6–83.9)*
|
| Estimated glomerular filtration rate, mL/min per 1.73 m2
|
91.8 (85.6–94.7)*
|
